Ameliorative Impact of Tecoma stans on Streptozotocin-Induced Diabetic Cardiomyopathy in Wistar Rats

Abstract

The objective of this study was to see how an ethanolic extract of Tecoma stans affected diabetic cardiomyopathy in wistar rats after streptozotocin-induced diabetes.  The pathogenesis of diabetic cardiomyopathy (DCM) is complex, and the therapeutic options available to treat DCM are limited. A single intravenous dosage of (Streptozotocin 45 mg/kg) produced diabetes in male wistar rats. Blood pressure, serum lactate dehydrogenase (LDH), glucose apolipoprotein B, and lipids were measured, as well as heart weight, caspase-3, sodium potassium adenosine triphosphatase (Na + -K + ATPase), and DNA laddering.  The obtained result showed that the administration of ethanolic extract of Tecoma stans (120 mg/kg/p.o.) significantly (P < 0.01) reduced myocyte loss by suppressing the levels of cardiac caspase-3, DNA laddering; mean arterial blood pressure and heart rate as well as serum LDH, glucose, apolipoprotein B and lipids levels. Further, it augmented the heart weight and cardiac Na+ K + ATPase activity in diabetic rats. Finally, an ethanol extract of Tecoma stans was found to have considerable anti-apoptotic potential in Streptozotocin-induced diabetic cardiomyopathy.